BUSINESS

• Evidence for Actair Sublingual Tablets “Sets It Apart from Other Therapies”: Shionogi
  August 22, 2016

• Oncolys, Kyoto Pref. University of Medicine to Study OBP-801 for Glaucoma
  August 19, 2016

• Amgen Confident of Getting Handsome Slice of Japan Biosimilar Market: Exec
  August 19, 2016

• CEO of Teva-Takeda JV Confident on Handling Both Long-Listed Brands, Generics
  August 17, 2016

• Ethical Drug Sales Down 0.8% in June: Crecon Report
  August 17, 2016

• Mitsubishi Tanabe to Focus on Sales Turnaround for Canaglu, Eyes Diabetes and Nephrology Sales of 100 Bil. Yen
  August 17, 2016

• Taiho Phama Subsidiary Gets Approval for Uzel AG
  August 16, 2016

• Japan NDA Filed for Gilead’s HIV Drug Descovy
  August 16, 2016

• Oncolys, NCC Hospital East to Run Investigator-Led Trial on Oncolytic Virus
  August 15, 2016

• AnGes MG, Vical to Form Biz Tie-Up over DNA Vaccines
  August 15, 2016

• Shionogi Begins Distribution of Ethical Isodine Products: Mundipharma
  August 15, 2016

• Teijin Gets Japan Rights to Versartis’ Growth Hormone Deficiency Treatment
  August 15, 2016

• JT/Torii License Menlo’s Pruritus Candidate for Japan Market
  August 15, 2016

• Sawai Eyes First-to-File Status for 5 Generics in the US
  August 10, 2016

• Japan PII Now Underway for Otsuka’s DMD Candidate TAS-205
  August 10, 2016

• Otsuka Suffers Big Drops in Pharma Sales, Profit on US Abilify Patent Loss
  August 10, 2016

• Astellas Files Japan NDA for Quetiapine for Bipolar Disorder
  August 10, 2016

• Kissei, JCR Kick Off Japan PIII for Nesp Biosimilar
  August 10, 2016

• Eisai, Biogen to Launch Global PIII for Alzheimer’s Drug by March-End
  August 10, 2016

• Ono Rushes to Soothe Investor Nerves over Opdivo PIII Data
  August 10, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 461
• 462
• 463
• 464
• 465
• 466
• 467
• 468
• 469
• …
• Next ›
• 最終 »